Palbociclib: beside a new treatment under test
88 studies: a new drug, cell therapy or vaccine is what the study tests. Page 1 of 1. Open to participants first (25), then studies with results posted, then the rest; newest registration first within each.
- A Phase 1/2a Study of K-1728 in Advanced Solid TumorsRecruitingNCT07861932Phase 1/2Report a problem
- A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid TumorsNot yet recruitingNCT07787520Phase 1Report a problem
- Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07191977Phase 2Report a problem
- Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast CancerRecruitingNCT07180160Phase 2Report a problem
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingNCT07174336Phase 3Report a problem
- A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast CancerNot yet recruitingNCT07173556Phase 1/2Report a problem
- A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell CarcinomaRecruitingNCT07123090Phase 2Report a problem
- Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast CancerRecruitingNCT07037199Phase 2Report a problem
- A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BCRecruitingNCT07002177Phase 1/2Report a problem
- A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsRecruitingNCT06997029Phase 1Report a problem
- A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS MutationsRecruitingNCT06947811Phase 1/2Report a problem
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)RecruitingNCT06757634Phase 3Report a problem
- A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast CancerNot yet recruitingNCT06757335Phase 1/2Report a problem
- SNV4818 in Participants With Advanced Solid TumorsRecruitingNCT06736704Phase 1/2Report a problem
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingNCT06380751Phase 3Report a problem
- Study of AVZO-021 in Patients With Advanced Solid TumorsRecruitingNCT05867251Phase 1/2Report a problem
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingNCT05768139Phase 1/2Report a problem
- A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast CancerRecruitingNCT05683418Phase 1Report a problem
- Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)RecruitingNCT05665361Phase 1/2Report a problem
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerRecruitingNCT05216432Phase 1Report a problem
- Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast CancerNot yet recruitingNCT04858516Phase 2Report a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingNCT04802759Phase 1/2Report a problem
- Study of PF-07248144 in Advanced or Metastatic Solid TumorsRecruitingNCT04606446Phase 2Report a problem
- Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid TumorsRecruitingNCT03454035Phase 1Report a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2Report a problem
- Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)TerminatedNCT05935748Phase 2Results postedReport a problem
- Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast CancerTerminatedNCT05384119Phase 1Results postedReport a problem
- Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast CancerTerminatedNCT04478266Phase 3Results postedReport a problem
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)CompletedNCT04436744Phase 2Results postedReport a problem
- A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast CancerActive, not recruitingNCT04288089Phase 1Results postedReport a problem
- Phase 2a Study of ZW25 in Combination With Palbociclib Plus FulvestrantCompletedNCT04224272Phase 2Results postedReport a problem
- A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerActive, not recruitingNCT04191499Phase 2/3Results postedReport a problem
- Palbociclib + Ganitumab In Ewing SarcomaTerminatedNCT04129151Phase 2Results postedReport a problem
- A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast CancerCompletedNCT04072952Phase 1/2Results postedReport a problem
- A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast CancerTerminatedNCT04060862Phase 1Results postedReport a problem
- A Study of ZN-c5 in Subjects With Breast CancerCompletedNCT03560531Phase 1/2Results postedReport a problem
- Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast CancerTerminatedNCT03284957Phase 1/2Results postedReport a problem
- PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid TumorsTerminatedNCT03284723Phase 1Results postedReport a problem
- Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast CancerCompletedNCT03238196Phase 1Results postedReport a problem
- Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast CancerCompletedNCT03054363Phase 1/2Results postedReport a problem
- Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)TerminatedNCT02349633Phase 1/2Results postedReport a problem
- ALRN-6924 in Patients With Advanced Solid Tumors or LymphomasCompletedNCT02264613Phase 1/2Results postedReport a problem
- A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast CancerTerminatedNCT01823835Phase 1/2Results postedReport a problem
- Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell CarcinomasActive, not recruitingNCT06654297Phase 1Report a problem
- ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast CancerCompletedNCT06570031Phase 1Report a problem
- A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsActive, not recruitingNCT06188520Phase 1/2Report a problem
- A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingNCT06065748Phase 3Report a problem
- Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerActive, not recruitingNCT05909397Phase 3Report a problem
- First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid TumorsCompletedNCT05759949Phase 1Report a problem
- TAS-116 Plus Palbociclib in Breast and Rb-null CancerWithdrawnNCT05655598Phase 1Report a problem
- Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)Active, not recruitingNCT05501886Phase 3Report a problem
- Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast CancerActive, not recruitingNCT05293964Phase 1Report a problem
- A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer PatientsActive, not recruitingNCT05266105Phase 1Report a problem
- Study of INCB123667 in Subjects With Advanced Solid TumorsActive, not recruitingNCT05238922Phase 1Report a problem
- Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)CompletedNCT05178888Phase 1Report a problem
- Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast CancerStatus unknownNCT05076695Phase 2Report a problem
- A Study of ERAS-007 in Patients With Advanced Gastrointestinal MalignanciesCompletedNCT05039177Phase 1/2Report a problem
- Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Active, not recruitingNCT04964934Phase 3Report a problem
- A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast CancerSuspendedNCT04946864Phase 1/2Report a problem
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2Report a problem
- Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA SuppressionActive, not recruitingNCT04920708Phase 2Report a problem
- A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast CancerWithdrawnNCT04872608Phase 1Report a problem
- Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Active, not recruitingNCT04862663Phase 3Report a problem
- Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast CancerStatus unknownNCT04856371Phase 1Report a problem
- AZD9833 China PK StudyCompletedNCT04818632Phase 1Report a problem
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseActive, not recruitingNCT04711252Phase 3Report a problem
- ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)Status unknownNCT04669587Phase 1/2Report a problem
- PF-07104091 as a Single Agent and in Combination TherapyActive, not recruitingNCT04553133Phase 2Report a problem
- A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)Active, not recruitingNCT04546009Phase 3Report a problem
- Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerWithdrawnNCT04498520Phase 1Report a problem
- Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.CompletedNCT04483505Phase 1Report a problem
- Palbociclib and INCMGA00012 in People With Advanced LiposarcomaActive, not recruitingNCT04438824Phase 2Report a problem
- Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in ChinaStatus unknownNCT04334330Phase 2Report a problem
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruitingNCT04185883Phase 1Report a problem
- A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid TumorsCompletedNCT03965845Phase 1/2Report a problem
- AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)Active, not recruitingNCT03959891Phase 1Report a problem
- Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingNCT03616587Phase 1Report a problem
- A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast CancerCompletedNCT03471663Phase 1Report a problem
- G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast CancerCompletedNCT03455270Phase 1Report a problem
- A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerActive, not recruitingNCT03332797Phase 1Report a problem
- Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung CancerCompletedNCT03170206Phase 1Report a problem
- Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast CancerTerminatedNCT03128619Phase 1Report a problem
- Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsSuspendedNCT03065062Phase 1Report a problem
- To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast CancerActive, not recruitingNCT03006172Phase 1Report a problem
- A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast CancerCompletedNCT02684032Phase 1Report a problem
- Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast CancerStatus unknownNCT02626507Phase 1Report a problem
- Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast CancerCompletedNCT02599714Phase 1Report a problem
- PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibCompletedNCT02389842Phase 1Report a problem